All News

Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.

Nubeqa plus hormone therapy improved outcomes in metastatic prostate cancer, reducing disease progression and showing a favorable safety profile.

Tara Sweeney, BSN, RN, OCN, CHPN discussed best care for the health and well-being of a person across all stages of their cancer survivorship.

Advancements in radiation therapy, including proton therapy and stereotactic radiation, reduce side effects and improve quality of life for GI cancer.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Experiencing spring's renewal after a cancer diagnosis, I focus on health through checkups, diet and exercise, embracing change and well-being.

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity and manageable safety.

A phase 1 clinical trial is open for enrollment to patients with high-grade neuroendocrine tumors.

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors.

Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

Some cancer statistics may reflect 'backwards-looking data', making it important to stay up to date on reliable information and happenings in the space.

Testicular cancer is rare but highly curable, especially with early detection; treatment varies by stage, and follow-up care supports long-term health.

Living with Lynch isn't easy, but it's not all doom and gloom. It's a call to live deliberately.

CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.

Dr. Sheri Yolanda Prentiss discusses the importance of seeking early intervention to detect lymphedema following cancer care.

I was diagnosed with stage 3 melanoma at 31, faced recurrence and now share my journey to raise awareness, stay hopeful and trust in God’s plan.

The FDA has approved Jobevne, a biosimilar to Avastin, for IV use in a number of cancer types.

It isn’t easy having cancer. But like gardening in a harsh climate, survival and growth come from strategies, adaptation, and patience.

Alliance advocates for greater awareness during April minority health month.

Vitrakvi, first granted accelerated approval in 2018, has received full approval from the FDA.

The 2025 Extraordinary Healer® Award was presented during the 50th Annual Oncology Nursing Society Congress, recognizing oncology nursing professionals' dedication and impact.

CT-95 is being developed for cancers including pancreatic, ovarian and mesothelioma and other solid tumors.

Because the five-year relative survival rate for people with esophageal cancer is approximately 22%, this makes early detection of the essence.

Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck cancer.